Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$26 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-24 Mln
ROE
-2.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.6
Industry P/E
24.51
EV/EBITDA
11
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.9
Face value
--
Shares outstanding
8,457,967
CFO
$-188.50 Mln
EBITDA
$-276.51 Mln
Net Profit
$-286.27 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CEL-SCI Corp (CVM)
| -34.0 | -18.5 | -34.0 | -47.3 | -63.2 | -62.9 | -37.8 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
CEL-SCI Corp (CVM)
| -56.2 | -85.1 | 15.7 | -66.9 | -39.1 | 27.4 | 218.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CEL-SCI Corp (CVM)
|
3.5 | 26.0 | 0.0 | -23.8 | -- | -262.1 | -- | 2.6 |
| 12.5 | 3,812.0 | 3,018.8 | 72.1 | 12.6 | -80 | 54.3 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.3 | 11,237.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.7 | 2.9 | |
| 23.1 | 11,474.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,099.9 | 158.3 | -68.9 | -29.3 | -113 | -- | 69.3 |
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has... completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. Address: 8229 Boone Boulevard, Vienna, VA, United States, 22182 Read more
Chief Executive & Financial Officer, Treasurer and Director
Mr. Geert R. Kersten Esq.
Chief Scientific Officer
Dr. Eyal Talor Ph.D.
Headquarters
Vienna, VA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of CEL-SCI Corp (CVM) is $3.47 (NYSE) as of 02-Apr-2026 16:50 EDT. CEL-SCI Corp (CVM) has given a return of -63.2% in the last 3 years.
Since, TTM earnings of CEL-SCI Corp (CVM) is negative, P/E ratio is not available.
The P/B ratio of CEL-SCI Corp (CVM) is 2.61 times as on 31-Mar-2026, a 54 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.90
|
4.62
|
|
2024
|
-0.08
|
0.18
|
|
2023
|
-0.06
|
0.14
|
|
2022
|
-0.12
|
0.14
|
|
2021
|
-0.38
|
0.27
|
The 52-week high and low of CEL-SCI Corp (CVM) are Rs 13.48 and Rs 1.98 as of 04-Apr-2026.
CEL-SCI Corp (CVM) has a market capitalisation of $ 26 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in CEL-SCI Corp (CVM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.04
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.